CORMEDIX INC

NASDAQ: CRMD (CorMedix Inc.)

Last update: 20 hours ago

4.82

0.16 (3.43%)

Previous Close 4.66
Volume 3,195,451
Price / Earnings (Forward) 33.21
Price / Sales 1.07
Price / Book 0.800
52 Weeks Range
4.65 (-3%) — 13.02 (170%)
Profit Margin 20.81%
Operating Margin (TTM) 51.49%
Diluted EPS (TTM) 0.250
Total Debt/Equity (MRQ) 0.41%
Current Ratio (MRQ) 4.21
Operating Cash Flow (TTM) -13.57 M
Levered Free Cash Flow (TTM) -21.07 M
Return on Assets (TTM) 8.31%
Return on Equity (TTM) 19.87%

AIStockmoo Score

-0.1
Value 30% 0.7
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Low debt. Strong profitability. Ample short-term liquidity. Negative cash flow. info
Earns below its cost of capital. Returns on capital rising. info
Timing 30% -3.4
From our AI technical analysis of the chart. info NA
Downtrend over the past year. Far below its 52-week high. info
Recent bullish reversal pattern: Inverted hammer. info
Trend for Your Holding Period info NA
Sentiment 20% 0.3
No recent price targets, so based on how targets have been revised. info
Recent news mixed or neutral. info
Smart Money 20% 3.5
Insider Activity info NA
Institutions net +5.68% of shares in their latest 13F filings: 99 holders increased, 90 decreased (quarter to 30 Sep 2026). info
Short interest -11.4% from 31 Aug to 30 Oct 2026, 8.4 days to cover (FINRA). info
Market and sector conditions are poor.
Market environment cautious. info
Sector lagging the market.
The pillars disagree, so the score is softened.
Not in score
Price is low against its 52-week average. info
Trend down on all three terms. Short-term momentum falling. info
No clear signal from support and resistance. info
Final Score -0.06

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock CorMedix Inc. Mixed Bearish

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
CRMD - - - 0.800
TRML 1 B - - 4.76
TECH - 0.44% - 5.28
MLTX - - - 2.79
VKTX - - - 6.33
VSTM - - - 76.50

Select this tab to load the latest available analysis.

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.

Sector Healthcare
Industry Biotechnology
Investment Style Small Core
% Held by Insiders 1.08%
% Held by Institutions 34.20%

No data within this time range.

No data within this time range.

Institutions

Institutional ownership: 64.78%

Positions Holders Shares
Increased 99 7,583,312
Decreased 90 3,469,708
New 31 1,461,982
Sold out 20 1,030,741

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

Short Interest

Settlement Shares Days to cover
30 Oct 2026 14,205,973 8.4
15 Oct 2026 14,665,697 12.7
30 Sep 2026 15,422,728 18.9
15 Sep 2026 16,202,272 18.5
31 Aug 2026 16,032,112 13.0
14 Aug 2026 17,149,908 11.1

FINRA short interest via Nasdaq, reported twice a month.

7 Positive 3 Negative 4 Neutral
Date Type Details
13 Nov 2026 Yahoo Finance CorMedix's DefenCath, Rezzayo to Drive 2027 Growth, Oppenheimer Says
CorMedix's (CRMD) DefenCath and Rezzayo medications are expected to drive 2027 growth, in addition t…
13 Nov 2026 Yahoo Finance CRMD Stock Down 9% Despite Q3 Earnings and Revenues Beat Estimates
CorMedix beats Q3 estimates, but DefenCath pricing pressure hurts sales. Rezzayo progress and the planned Heron acquisition shape its 2027 outlook.
12 Nov 2026 Yahoo Finance CorMedix Inc. Q3 2026 Earnings Call Summary
Moby summary of CorMedix Inc.'s Q3 2026 earnings call…
12 Nov 2026 Yahoo Finance CorMedix (CRMD) Q3 2026 Earnings Call Transcript
Heron deal and DefenCath reimbursement shifts drive the quarter.
12 Nov 2026 Yahoo Finance What CorMedix (CRMD) Said on Its Q3 Earnings Call
CorMedix (NASDAQ:CRMD) reported lower third-quarter revenue as its DefenCath product entered a new reimbursement period, while management outlined plans to acquire substantially all of Heron Therapeutics’ assets and deferred 2027 guidance for the dialysis treatment. Revenue fell to $54.5 million fr…
12 Nov 2026 Yahoo Finance CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates
CorMedix (CRMD) delivered earnings and revenue surprises of +55.56% and +3.89%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
12 Nov 2026 Yahoo Finance CorMedix: Q3 Earnings Snapshot
(CRMD) on Thursday reported a loss of $14.On a per-share basis, the Parsippany, New Jersey-based company said it had a loss of 19 cents.
12 Nov 2026 Yahoo Finance Cormedix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
‒ Recently announced acquisition of assets of Heron Therapeutics – ‒ Q3 2026 consolidated revenue of $54.5 million ‒ ‒ Q3 2026 net loss of $14.7 million; Adjusted EBITDA of $3.1 million ‒ ‒ Company maintains FY 2026 revenue and narrows Adjusted EBITDA guidance ‒ ‒ Conference call scheduled for…
10 Nov 2026 Yahoo Finance CRMD to Acquire HRTX Assets for $223M Upfront to Expand Portfolio
CorMedix is set to acquire HRTX's commercial assets for $223 million upfront, adding four products, expanding its hospital reach and targeting significant cost synergies.
10 Nov 2026 Yahoo Finance CorMedix to Acquire Heron Assets, Adding Four Products and Targeting Up to $60 Million in Savings
CorMedix (NASDAQ:CRMD) has agreed to acquire substantially all of Heron Therapeutics’ assets, adding four commercial products and a development agreement to its portfolio of medicines used in hospitals and other institutional settings. CorMedix will pay $145 million in cash and approximately 14.6 m…
09 Nov 2026 Yahoo Finance CorMedix stock gains as Heron deal adds four products
Investing.com -- CorMedix Inc (NASDAQ:CRMD) shares rose 4.5% in premarket trading Monday after the company announced it will acquire substantially all assets of Heron Therapeutics Inc (NASDAQ:HRTX) for approximately $222.6 million. Heron stock surged 45% on the news.
09 Nov 2026 Yahoo Finance CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care
Adds four commercial-stage products — ZYNRELEF®, APONVIE®, CINVANTI® and SUSTOL® — to CorMedix's hospital- and acute-care-focused commercial platform Upfront consideration consisting of $145 million in cash, subject to customary purchase price adjustments, plus 14,583,333 shares of CorMedix common…
06 Nov 2026 Yahoo Finance CorMedix Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
PARSIPPANY, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the third quarter ended September 30, 2026, before the market opens on Thursday, November 12, 2026, and will host a corporate update conference call…
04 Nov 2026 Yahoo Finance Earnings Preview: CorMedix (CRMD) Q3 Earnings Expected to Decline
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
02 Nov 2026 Yahoo Finance CorMedix Reaffirms 2026 Revenue Guidance of $325 Million–$345 Million and Reports $355 Million Cash Position
CorMedix Therapeutics (NASDAQ:CRMD) has maintained its full-year 2026 revenue guidance of $325 million to $345 million and reported approximately $355 million in unaudited cash and cash equivalents as of September 30, 2026, according to a business update released on November 2. The pharmaceutical…
02 Nov 2026 Yahoo Finance CorMedix Therapeutics Provides Business Update, Reaffirms 2026 Total Revenue Guidance, and Reports Third Quarter Cash Position
PARSIPPANY, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today provided a business update in advance of a conference call expected to be held on November 12, 2026 to discuss the Company’s complete quarterly financial performance. Business Updates CorMedix announces…
Show more

Recent Signals candle patterns and EMA crosses

▲ Inverted hammer 2 sessions ago · 12 Nov
A small body with a long upper shadow after a decline: buyers are testing higher. Needs a higher close next to confirm.

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria